

SUPPLEMENTARY MATERIAL

Table 1. Baseline and clinical patient characteristics in patients with persistent mild GBS.

	Supportive care group n=29	IVIg group n=82	p-value
Male, n (%)	17 (59)	57 (70)	0.29
Age, y, median (IQR)	54 (33-59)	43 (34-58)	0.32
Region, n (%)			0.03
Europe	24 (83)	58 (71)	
Americas	2 (7)	15 (18)	
Asia	1 (3)	9 (11)	
Africa	2 (7)	0 (0)	
Australia	0 (0)	0 (0)	
Antecedent event, n (%)			
URTI	13/28 (54)	34 (42)	0.27
Diarrhoea	5/28 (18)	28 (34)	0.10
Other	3/28 (11)	9 (11)	1.00
None	5/28 (18)	11 (13)	0.57
CHARACTERISTICS AT ENTRY			
Pain, n (%)	15/28 (54)	40 (49)	0.66
Cranial nerve involvement, n (%)	8 (28)	27 (33)	0.60
Oculomotor	1 (3)	4 (5)	1.00
Facial	6 (21)	21 (26)	0.60
Bulbar	1 (3)	8 (10)	0.44
MRC sum score, median (IQR)	54 (52-58)	55 (51-58)	0.99
Sensory deficits, n (%)	14 (48)	48 (59)	0.34
Ataxia, n (%)	6/28 (21)	24/78 (31)	0.35
GBS disability score, n (%)			0.32
Minor symptoms (1)	5 (17)	8 (10)	
Able to walk independently (2)	24 (83)	74 (90)	
Autonomic dysfunction, n (%)	0/28 (0)	14 (17)	0.02
GBS clinical variant ¹ , n (%)			
Sensorimotor	18 (62)	63 (77)	0.12
Pure motor	9 (30)	13 (16)	0.08
MFS-GBS-overlap	1 (3)	4 (5)	1.00
Pharyngeal-cervical-brachial	1 (3)	2 (2)	1.00
ADDITIONAL INVESTIGATION			
Electrophysiological classification (n, %)			
Demyelinating	10/25 (40)	40/70 (57)	0.14

Axonal	1/25 (4)	2/70 (3)	1.00
Inexcitable	0/25 (0)	0/70 (0)	na
Equivocal	13/25 (52)	24/70 (34)	0.12
Normal	1/25 (4)	4/70 (6)	1.00

¹ Determined at week 2

Abbreviations: GBS = Guillain-Barré syndrome, IQR = interquartile range, IVIg = intravenous immunoglobulin, MFS = Miller Fisher syndrome, MRC = Medical Research Council, na = not applicable, URTI = upper respiratory tract infection